Conatus Continues New HCV Drug Development

In addition to Merck and Vertex, Conatus is another company investing in the development of new hepatitis C therapies. Overall, the number of companies involved in hepatitis C drug development is close to a dozen, which is exciting to see. As time passes, there will be continued opportunities to participate in clinical research protocols, as these agents move through the FDA approval process.

For more information on Conatus, read the article here.

Tags: , ,

No comments yet.

Leave a Reply